News | June 28, 2022
Balaxi Pharmaceuticals' Hyderabad factory to be operational by March 2024
This facility will produce higher efficacy products that enjoy greater acceptance and enhanced profit marginsg
This facility will produce higher efficacy products that enjoy greater acceptance and enhanced profit marginsg
First and only PARP inhibitor to improve invasive disease-free survival in patients
The FDA informed Astellas that it did not have sufficient information to assess the risks to subjects
Both vaccine candidates demonstrated a favorable safety and tolerability profile similar to the Pfizer-BioNTech COVID-19 Vaccine
Tabrecta is the number one prescribed targeted therapy for advanced NSCLC with alterations leading to METex14 skipping globally
An interim analysis of this data shows no significant safety issues and a 91% seroconversion rate at Day 56.
It´s the first trial to demonstrate the benefits of dual pathway inhibition
The 41,000 sq ft facility will be utilized to manufacture clinical to commercial-grade peptide products for increased manufacturing capacity
This new €59 million, 70,000 square foot facility, officially opened today, brings 50 new jobs to the area
Intended for potential treatment of ER+/HER2- advanced or metastatic breast cancer patients
Subscribe To Our Newsletter & Stay Updated
